UK's Oxford BioMedica H1 revenue rises on increased manufacturing
(This story was generated using AI and automation, please see disclaimer ) Overview UK cell and gene therapy CDMO's H1 revenue rose 9% yr/yr, matching analyst estimate Adjusted operating EBITDA loss narrowed to £2.5 mln from £3.9 mln a year earlier Gross margin fell to 37% from 43% due to product and client mix changes